Thiotriazolin gets a state award for innovation
On May 19, an official ceremony was held to award the Cabinet of Ministers of Ukraine Prize Laureate Diplomas to developers of Thiotriazolin. The prize was bestowed on them for creation and manufacturing of the drugs that target cardiovascular and ophthalmic diseases and improve the immunological response of the organism.
Established by the Cabinet of Ministers of Ukraine in 2012, the prize is awarded annually for outstanding achievements in the development and introduction of new technologies in production, as well as for launching innovative domestic products.
Thiotriazolin is one of Arterium Corporation's original medicinal products. A cardioprotective drug, it is used in the treatment of coronary artery disease (CAD). Its manufacturing was launched back in 1994, when Galychpharm in cooperation with Pharmatron started making Thiotriazolin in the form of injection solution in ampoules. In 1995, production of Thiotriazolin in tablets followed.